Trinity Biotech (FRA:TRB0) Tariff Resilience Score: 3/10 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TRB0 Trinity Biotech PLC FRA:TRB0
28 GF Score
Price €2.12
GF Value €4.48
! 7 Warning Signs
View Full Analysis

What is Trinity Biotech Tariff Resilience Score?

Trinity Biotech FRA:TRB0 28 Tariff Resilience Score is 3 as of Jul. 17, 2026. GuruFocus rates FRA:TRB0 with a GF Score™ of 28/100 and a GF Value™ of €4.48. The stock has 7 warning signs investors should review. Among 834 Medical Devices & Instruments companies, Trinity Biotech ranks better than 66.67% on this metric.

Trinity Biotech has the Tariff Resilience Score of 3, which implies that the company might have .

Trinity Biotech has High vulnerability due to global supply chain dependencies and international sales. Previous tariffs have increased costs, and the company has limited ability to pass on costs due to competitive pressures.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Trinity Biotech might have .

Trinity Biotech  (FRA:TRB0) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Trinity Biotech Tariff Resilience Score Related Terms

FRA:TRB0 vs AIDX, NVNO, STME: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Trinity Biotech's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trinity Biotech Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Tariff Resilience Score falls into.


FRA:TRB0
28GF Score
Trinity Biotech PLC FRA:TRB0
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 3 mean?
Trinity Biotech (FRA:TRB0) has a Tariff Resilience Score of 3 as of Jul. 17, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Trinity Biotech ranks #278 out of 834 companies in the Medical Devices & Instruments industry, placing it in the top 33.3%.
Is Trinity Biotech's Tariff Resilience Score too high?
Trinity Biotech's current Tariff Resilience Score is 3. Based on the distribution chart, Trinity Biotech ranks #278 out of 834 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Trinity Biotech has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Tariff Resilience Score compare to AIDX and NVNO?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #278 out of 834 companies for Tariff Resilience Score. This puts Trinity Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Trinity Biotech's current Tariff Resilience Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Trinity Biotech (FRA:TRB0) has a current Tariff Resilience Score of 3. The stock's GF Value™ is €4.48, compared to a current price of €2.12 — trading 52.7% below its estimated fair value. The current Tariff Resilience Score is 3. Trinity Biotech's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Trinity Biotech (FRA:TRB0), the current Tariff Resilience Score is 3 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Trinity Biotech (FRA:TRB0) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of €2.12 is trading 52.7% below its estimated GF Value™ of €4.48.

Key valuation signals for FRA:TRB0:

  • Tariff Resilience Score: 3
  • GF Value™: €4.48 vs. price of €2.12 (52.7% below fair value)
  • GF Score™: 28/100 with 7 warning signs

No single metric tells the full story. See the FRA:TRB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Trinity Biotech Business Description

Other Exchanges TRIB:USA
Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
28GF Score

Get the complete analysis for FRA:TRB0

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.12
Price
€4.48
GF Value